Author:
Solomon Todd M.,Hajduk Matus,Majernik Martin,Jemison Jamileh,Deschamps Alexander,Scoggins Jenna,Kolar Adam,Pinheiro Miguel Amável,Dubec Peter,Skala Ondrej,Muir Owen,Tinkelman Amanda,Karlin Daniel R.,Barrow Robert
Abstract
Spravato and other drugs with consciousness-altering effects show significant promise for treating various mental health disorders. However, the effects of these treatments necessitate a substantial degree of patient monitoring which can be burdensome to healthcare providers and may make these treatments less accessible for prospective patients. Continuous passive monitoring via digital devices may be useful in reducing this burden. This proof-of-concept study tested the MindMed Session Monitoring System™ (MSMS™), a continuous passive monitoring system intended for use during treatment sessions involving pharmaceutical products with consciousness-altering effects. Participants completed 129 Spravato sessions with MSMS at an outpatient psychiatry clinic specializing in Spravato treatment. Results indicated high rates of data quality and self-reported usability among participants and health care providers (HCPs). These findings demonstrate the potential for systems such as MSMS to be used in consciousness-altering treatment sessions to assist with patient monitoring.
Subject
Health Informatics,Medicine (miscellaneous),Biomedical Engineering,Computer Science Applications
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Esketamine in depression: putative biomarkers from clinical research;European Archives of Psychiatry and Clinical Neuroscience;2024-07-13